REACH-2

NCT02435433 📎

Regimen

Experimental
ramucirumab 8 mg/kg IV Q2W + BSC
Control
placebo + BSC

Population

Advanced hepatocellular carcinoma with AFP >=400 ng/mL, BCLC B/C, Child-Pugh A, prior 1L sorafenib

Key finding

mOS 8.5 vs 7.3 mo (HR 0.71, 95% CI 0.53-0.95, p=0.0199); mPFS 2.8 vs 1.6 mo (HR 0.45, p<0.0001); biomarker entry: **AFP ≥400 ng/mL** (after REACH in all-comers was negative, HR 0.87); etiology HBV 36%, HCV 26%

Source: PMID 30665869

Timeline

    Guideline citations

    • NCCN HCC (p.28)